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Abstract
Purpose: Prospective–retrospective assessment of the TOP1
gene copy number and TOP1 mRNA expression as predictive
biomarkers for adjuvant irinotecan in stage II/III colon cancer.
Experimental Design: Formalin-fixed, paraffin-embedded
tissue microarrays were obtained from an adjuvant colon
cancer trial (PETACC3) where patients were randomized to
5-fluorouracil/folinic acid with or without additional irinote-
can. TOP1 copy number status was analyzed by fluorescence
in situ hybridization (FISH) using a TOP1/CEN20 dual-probe
combination. TOP1 mRNA data were available from previous
analyses.
Results: TOP1 FISH and follow-up data were obtained from
534 patients. TOP1 gain was identified in 27% using a single-
probe enumeration strategy (4 TOP1 signals per cell) and in
31% when defined by a TOP1/CEN20 ratio  1.5. The effect of
additional irinotecan was not dependent on TOP1 FISH status.
TOP1mRNA data were available from 580 patients with stage III
disease. Benefit of irinotecan was restricted to patients character-
ized by TOP1mRNA expression  third quartile (RFS: HRadjusted,
0.59; P ¼ 0.09; OS: HRadjusted, 0.44; P ¼ 0.03). The treatment by
TOP1 mRNA interaction was not statistically significant, but in
exploratory multivariable fractional polynomial interaction anal-
ysis, increasing TOP1 mRNA values appeared to be associated
with increasing benefit of irinotecan.
Conclusions: In contrast to theTOP1 copy number, a trendwas
demonstrated for a predictive property of TOP1 mRNA expres-
sion. On the basis of TOP1mRNA, it might be possible to identify
a subgroup of patients where an irinotecan doublet is a clinically
relevant option in the adjuvant setting of colon cancer. Clin Cancer
Res; 22(7); 1621–31. 2015 AACR.
Introduction
Colorectal cancer is one of the leading causes for cancer related
mortality in the world (1–3). Tumor stage at diagnosis remains
the strongest prognostic factor, and treatment is guided according
to the TNM staging system (4–8). Systemic treatment has
improved progression-free survival (PFS) and overall survival
(OS) for patients with advanced disease, but survival benefit of
adjuvant systemic therapy is also evident for patients with high-
risk localized disease (high-risk stage II) or regional disease (stage
III; ref. 9). A limitation of systemic therapy is the great interpatient
variability in drug efficacy and severity of adverse effects (10). In
the pursuit of a more personalized treatment approach, it is
clinically important to identify tumor characteristics that may
serve as biomarkers whichwill accurately predict the likelihood of
benefit in advance of therapy. The discovery and validation of
predictive biomarkers are not only relevant in the development of
new targeted drugs, but may be equally important for already
implemented classic cytotoxic chemotherapy.
The introduction of irinotecan in combination with 5-fluo-
rouracil (5FU)/folinic acid (FA; e.g., FOLFIRI) has improved the
clinical outcome of patients with metastatic colorectal cancer,
and with efficacy equal to that of the oxaliplatin and 5FU/FA
doublets, the FOLFIRI regimen is approved for first and second
line therapy (9, 11–13). However, overall objective response
rates following FOLFIRI remains below 50% and in combina-
tion with noncomplete cross-resistance between FOLFIRI and
the oxaliplatin doublets this emphasizes the importance of
selecting the right treatment regimen in first line (12–14).
Irinotecan is not recommended in the adjuvant setting of colon
cancer because superiority of the 5FU/FA þ irinotecan combi-
nations over 5FU/FA alone has not been demonstrated in any
randomized controlled trials (RCT; refs. 15–18). However, the
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conclusions from these RCTs are based on average efficacy
measures that might conceal subpopulations of patients who
benefit greatly from additional irinotecan.
Irinotecan is a semi-synthetic derivative of camptothecin, a
cytotoxic alkaloid that exerts its activity by transforming DNA
topoisomerase 1 (Top1) into a potent cellular toxin (19). Accord-
ingly, irinotecan may be regarded as targeted cytotoxic therapy
(20). The biologic function of Top1 is to relax the DNA super-
coiling that emerges through DNA transcription and replication.
This is achieved through the formation of functional Top1-DNA
cleavage complexes (Top1cc) that in a controlled way allow for
transient single-stranded DNA breaks. The active form of irino-
tecan stabilizes the Top1cc by interfacial inhibition, and as a result
the rapidmovingDNAandRNApolymerases catch up and collide
with these stalled complexes whereby irreversible Top1-DNA
cross-links are formed (20, 21).
Elevated Top1 protein levels will in theory result in increased
cytotoxic activity of irinotecan, and based on in vitro cell line
studies, Top1 protein has been suggested as a putative predictive
biomarker (22–26). Attempts to clinically validate these findings
in the setting of advanced colorectal cancer have been carried out
in two well-designed retrospective biomarker studies (27, 28).
However, the results from these studies are conflicting, and in
addition, inconclusive findings have been published for the
predictive property of Top1 protein expression in the adjuvant
setting (29). This inconsistency may partly be due to inherent
analytical limitations of the applied anti-Top1 antibody for
immunohistochemistry (IHC), and reports of lack of reproduc-
ibility of Top1 staining results have been published recently (30).
The TOP1 gene copy number and TOP1 mRNA expression
represent potential alternatives to Top1 protein expression as
predictive biomarker candidates for irinotecan (31–33). We have
developed a gene enumeration TOP1/centromere-20 (CEN20)
dual-probe for fluorescence in situ hybridization (FISH), and in a
recently published study we demonstrated that TOP1 gene gain is
associated nonsignificantly with increased odds for response
following irinotecan monotherapy in patients with metastatic
colorectal cancer (34).
In 2009, Simon and colleagues (35) proposed new guidelines
for the use of archived tissuematerial in the assessment ofmedical
utility of biomarkers. The PETACC3 trial is a large randomized
phase III trial (ClinicalTrials.gov NCT00026273) where the study
protocol allowed for prospective collection of formalin-fixed,
paraffin-embedded (FFPE) tumor material (17). Although failing
to generate evidence for superiority of adding irinotecan to
5FU/FA in the adjuvant setting of colon cancer, considering the
guidelines of Simon and colleagues (35), the trial design seems
ideal for prospective–retrospective assessment of predictive bio-
markers for irinotecan. In the setting of the PETACC3 trial, we
report the results of a prospective–retrospective analysis of the
predictive property of TOP1 gene copy number status, assessed by
FISH, and TOP1mRNA expression status in relation to additional
irinotecan therapy. We hypothesize that a subpopulation of
patients benefit greatly from an irinotecan doublet in early stage
colon cancer, and that this subpopulation can be identified by
intratumoral TOP1 gene gain and/or by high TOP1mRNA expres-
sion levels.
Materials and Methods
Patients and tumor material
A total of 3,278 patients were accrued to the PETACC3 trial
(17). Patients were 18 and 75 years of age, with completely
resected histologically verified stage II or stage III adenocarcinoma
of the colon. Patients were stratified by disease stage and partic-
ipating center and randomly allocated to receive 6 months of
either 5FU/FA alone or 5FU/FA in combination with irinotecan.
Information on all eligibility criteria, the treatment schedules and
follow-up was accounted for in detail in the original publication
(17). Written informed consent, including permission for future
translational research using biological samples, was obtained
from all patients prior to study inclusion. FFPE samples from
1,564 patients were prospectively collected during the PETACC3
study accrual (36, 37), and tissue from 675 of these patients was
transferred to tissue micro arrays (TMA; refs. 36, 38). In brief,
central and peripheral tumor target areas were identified in
hematoxylin-eosin (H&E) stained sections, and for each patient
five 0.6-mm tissue cores from the corresponding FFPE donor
blocks were transferred to the recipient TMA blocks using a
manual tissue arrayer. Approval for the present translational study
was obtained from the PETACC3 Translational ResearchWorking
Party (PTRW).
TOP1 FISH
A TOP1/CEN20 probe combination and the Dako Histology
FISH Accessory Kit (Dako Denmark, Glostrup, Denmark) were
used as previously reported (32). The FISH dual-probe was
developed and analytically validated by Dako Denmark and the
University of Copenhagen (Copenhagen, Denmark; ref. 32). In
brief, the TOP1 gene probe is constructed from two bacterial
artificial chromosome (BAC) clones, RP11-629I4 and CTD-
3193L13. The final 370-kb probe covers the complete TOP1
genomic sequence of 96 kb at 20q12. Probes made from cloned
DNA will inevitably cross-hybridize to the repetitive sequences
that are interspersed randomly within coding and noncoding
regions. To avoid this cross-hybridization, the probe mixture
comprises unlabeled chemically synthesized peptide nucleic acid
(PNA) oligonucleotides that block the most frequent repetitive
sequences within the Alu repeat DNA sequence family. The
Translational Relevance
Validated predictive biomarkers for irinotecan will have
immediate clinical utility in themetastatic setting of colorectal
cancer. Additionally, such biomarkers will potentially identify
patients with localized and regional colon cancer where an
irinotecan doublet may be superior to standard oxaliplatin-
based adjuvant therapy. In the present study,we demonstrate a
trend for a TOP1 mRNA-dependent differential treatment
effect of irinotecan using a prospective–retrospective study
design and prospectively collected tumor samples from the
adjuvant colon cancer PETACC3 trial. High TOP1 mRNA
primary tumor expression levels are associated with benefit
of additional irinotecan compared with 5-fluorouracil mono-
therapy, whereas no effect of irinotecan is seen in patients with
low or normal TOP1mRNA expressing tumors. If these results
are confirmed, irinotecan may be an additional option in the
adjuvant setting of colon cancer. Furthermore, TOP1 mRNA
expression may prove to be a key predictor of irinotecan
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CEN20 probe is constructed from chromosome 20 centromere
specific PNA oligonucleotides. The two probes are labeled by
different fluorophores to allow for simultaneous target visuali-
zation by fluorescence microscopy when using an appropriate
dual-band filter. The fluorophores for this specific probe mixture
are composed of Texas Red for TOP1 and fluorescein isothiocy-
anate (FITC) for CEN20.
Probe sensitivity and specificity was tested by Dako using
metaphase chromosome preparations from normal diploid
cells. The probes hybridized to their expected localizations and
cross-hybridization to nonrelevant targets was not demonstrat-
ed. The probe mixture was optimized for the Dako Histology
FISH Accessory Kit (Dako) in the development phase. An
additional in-house optimization of the enzymatic digestion
time was performed using TMAs composed of normal and
neoplastic colon and rectal tissue. This was done in concor-
dance with the quality measures of the Section E9 of the
American College of Medical Genetics technical standards and
guidelines for FISH.
The hybridized TMA sections were evaluated using a fluores-
cence microscope (Zeiss AX10). The DAPI counterstain was used
to assess nuclear morphology and the TOP1 and CEN20 fluores-
cent signals were evaluated separately in relevant single filters and
in combination in a double filter. At medium magnification
(400x), quality and potential heterogeneity in the signal distri-
bution was assessed in all tissue cores from all patients. Signal
enumerationwas only performed in tumors showingwell defined
nuclear morphology and distinct fluorescent signals at medium
magnification. The signals were enumerated in 60 nonoverlap-
ping cancer cell nuclei at high magnification (1000x). In case of
heterogeneous signal distribution, the tumor areas with the high-
est number of TOP1 signals per nuclei were to be used for signal
enumeration. The TMA sections were evaluated by a pathologist
or a laboratory technician, who was well trained in the FISH
technique and the histological appearance of colon cancer. To
evaluate interobserver agreement, tumor cores from 42 patients
were evaluated by both observers. FISH procedures and scoring
were performed blinded to all patient data. To avoid missing a
potential TOP1 gene dosage effect, the average number of TOP1
signals per cell was used in parallel with the TOP1/CEN20 ratio to
determine TOP1 FISH status.
TOP1 mRNA expression
TOP1 mRNA gene expression data were generated previously
using the whole set of 1,564 samples (36, 39). In brief, FFPE
tumor blocks from 1,404 patients were eligible for RNA extrac-
tion. From corresponding micro-dissected tissue sections, RNA
of sufficient quantity and quality was successfully extracted
from 895 samples. Amplified products were hybridized to the
Almac Colorectal Cancer DSA microarray platform (Almac,
Craigavon, United Kingdom; ref. 40). Following quality con-
trol, TOP1 mRNA expression data were available for a total of
688 unique samples, including 580 from patients with stage III
disease.
Study design and statistical methods
The study design was prospective–retrospective as proposed by
Simon and colleagues (35), and the statistical plan and the
applied cutoff values were defined prior to FISH analysis. The
design included three biomarker study populations which were
named: TOP1 FISH stage II þ III, TOP1 FISH stage III, and TOP1
mRNA expression stage III. All populations were stratified accord-
ing to TOP1 status and treatment randomization. The REMARK
guidelines for reporting on biomarker studies were followed as
close as possible (41).
In adherence with previous publications addressing biomar-
kers in the PETACC3 material, the original primary study end-
point, disease-free survival (DFS), was rejected in favor of recur-
rence-free survival (RFS; ref. 42). In doing so, secondary primary
malignancies other than colon cancer were disregarded as events.
RFS was defined as time in months from randomization until the
occurrence of local, regional, or distant relapse; a second primary
colon cancer; or death. OS was retained as secondary endpoint
and was defined as time in months from randomization until
death.
For initial analyses, the average number of TOP1 signals per
cell, the TOP1/CEN20 ratio and the TOP1 mRNA expression
data were treated as continuous variables. To be able to
discriminate prognostic and predictive properties, patients
were dichotomized in TOP1 subgroups, categorized as TOP1
normal and TOP1 gained/TOP1 high, which was followed by
analyses of treatment effects within these subgroups. TOP1
gain was defined as an average TOP1 gene copy number  4.0
signals per cell or a TOP1/CEN20 ratio  1.5. In relation to the
TOP1 mRNA expression data, the third quartile was chosen to
dichotomize the population in TOP1 normal and TOP1 high
subgroups.
The Kaplan–Meier method was used to estimate RFS and OS
rates, and univariate comparisons were made using the log rank
test. The effect size of TOP1 status and treatment arm was
estimated in univariate and multivariable analysis using the Cox
proportional hazards model. Adjustment variables for multivar-
iable analysis were selected based on significant effects (P < 0.05)
in univariate analysis. Microsatellite instability (MSI), KRAS, and
BRAF status were available from previous publications (36,
37, 42), and these were tested alongside the clinical and patho-
logical baseline variables: N stage, tumor localization, tumor
grade, sex, and age. Formal tests for statistical interaction between
dichotomized TOP1 status and treatment were performed in
separate Cox models, including main effects and an interaction
term. All results were presented by hazard ratios (HR), estimated
95% confidence intervals (CI) and P values from the Wald-test.
BasedonSchoenfeld residuals no important violations against the
assumption of proportional hazards were identified for any of the
variables. A secondary exploratory multivariable fractional poly-
nomial interaction (MFPI) approach was performed to decrease
the risk of making a type II error (43, 44). Linear, FP1 and FP2
models (flexibility 1) with default parameters and MSI, KRAS,
BRAF, tumor localization, and N stage as adjusting variables were
tested in the MFPI analysis.
The c2 test was used for testing representativeness of the
biomarker study populations in relation to the PETACC3 popu-
lation as a whole. Likewise, the c2 test was used for assessing
potential differences in the distribution of the baseline variables
between the TOP1 subgroups. The P values from the c2 tests were
Bonferroni corrected to adjust for multiple comparisons. Pearson
correlation coefficients (r) were calculated to test for statistical
dependence between the TOP1 variables.
All P values were two-sided and the significance level was set
at <0.05. The MFPI analysis was performed in STATA 11 (45).
All other analyses were performed in R software for statistical
computing (R, 2013), version 3.0.2 (46).
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Results
All assays were conducted blinded to the clinical data. A total of
110patients (16.3%)were excluded following FISHprocedures as
a result of TMA core loss, weak fluorescent signal intensity, or
poorly preserved nuclear morphology. In addition, 31 patients
(4.6%) were excluded due to unsuccessful matching of the TMA
patient identification numbers with the clinical database. This
reduced the TOP1 FISH stage II þ III population to 534 patients
and the TOP1 FISH stage III population to 368 patients. The TOP1
mRNA stage III population was composed of 580 patients (for
CONSORT diagram see Supplementary Fig. S1). The treatment
randomization was well preserved in all three biomarker popula-
tions, and in relation to the baseline characteristics, the patients
were representative of those accrued to the PETACC3 trial as a
whole (Supplementary Tables S1 and S2). In adherence with the
results of the PETACC3 trial, benefit of additional irinotecan was
not identified in any of the biomarker populations (Supplemen-
tary Table S3).
The average TOP1 copy number ranged from 1.4 to 11.6 TOP1
signals per cellwhen including all unique sampleswith acceptable
hybridization quality (median ¼ 2.6). Similarly, the range of the
TOP1/CEN20 ratio was 0.8 to 3.9 (median¼ 1.3). In the 42 cases
where the FISH signals were counted by both observers, the Lin
concordance correlation coefficient for interobserver agreement
wasCCC¼0.99 (95%CI, 0.98–0.999) for theTOP1 copy number
per cell and CCC ¼ 0.96 (95% CI, 0.93–0.98) for the TOP1/
CEN20 ratio (for Bland-Altman plots see Supplementary Fig. S2).
In the TOP1 FISH stage II þ III population, 142 tumors (27%)
had4 TOP1 signals per cell and 167 tumors (31%) had a TOP1/
CEN20 ratio of 1.5. In the TOP1 FISH stage III population, 95
tumors (26%) had 4 TOP1 signals per cell while 120 tumors
(33%) had a TOP1/CEN20 ratio of 1.5. Apart from tumor
localization, where TOP1 gain, either as 4 TOP1 signals per cell
or a TOP1/CEN20 ratio of1.5, was observed more frequently in
left-sided tumors than in right-sided tumors, TOP1 FISH status
and TOP1 mRNA expression status did not associate with any
baseline characteristics (Supplementary Tables S4–S8). No sta-
tistically significant correlation was observed between the TOP1/
CEN20 ratio and TOP1 mRNA expression (r ¼ 0.25) or between
the TOP1 gene copy number and TOP1 mRNA expression
(r ¼ 0.25; Supplementary Fig. S3).
Prognostic and predictive effects of TOP1 FISH status
In univariate analyses not stratified by treatment, increasing
values of the TOP1/CEN20 ratio were associated with prolonged
OS in the FISH stage IIþ III population (HR, 0.74; 95% CI, 0.58–
0.95; P ¼ 0.01) and in the FISH stage III population (HR, 0.74;
95% CI, 0.56–0.97; P ¼ 0.02). Statistical significance was lost
when dichotomizing the populations by a TOP1/CEN20 ratio of
1.5 (Table 1). The association was not significant between the
TOP1/CEN20 ratio and RFS (Table 1). When the TOP1 gene copy
number per cell was modeled continuously or dichotomized by
4.0 TOP1 signals per cell, the associations with RFS andOSwere
nonsignificant both in the FISH stage IIþ III and the FISH stage III
populations (Table 1).
In search of a predictive property of TOP1 FISH status that was
independent of its potential inherent prognostic property, anal-
yses of treatment effects were performed separately in the TOP1
gained subgroups and theTOP1normal subgroups.No significant
separation of the Kaplan–Meier survival curves was identified for
treatment stratum in any TOP1 subpopulation (Fig. 1), and the
estimated 5-year RFS and OS rates were almost identical within
each TOP1 subgroup (Table 2 and Table 3).
In the exploratory MFPI analyses, BRAF status was selected as a
prognostic variable for which the models were adjusted. No
statistically significant treatment by TOP1 interaction was dem-
onstrated in any of the linear or flexible models where the TOP1
gene copy number and the TOP1/CEN20 ratio were retained on a
continuous scale in separate models (data not shown).
Prognostic and predictive effects of TOP1 mRNA expression
status
In univariate analysis including all available patients, contin-
uous increase in TOP1 mRNA expression was significantly asso-
ciated with prolonged OS (HR, 0.74; 95% CI, 0.60–0.92; P ¼
0.007) and nonsignificantly with prolonged RFS (HR, 0.85; 95%
CI, 0.7–1.03; P¼ 0.10). When the analysis was repeated using the
thirdquartile as cutoff value, statistical significancewas lost for the
Table 1. Univariate combined prognostic and predictive effects of TOP1 status in relation to recurrence-free survival and OS
Recurrence-free survival OS
No. HR (95% CI) P HR (95% CI) P
TOP1 FISH stage II þ III 534
TOP1 signals per cell
Continuous 0.96 (0.76–1.22) 0.76 0.84 (0.62–1.12) 0.22
Gain vs. normal 0.86 (0.60–1.22) 0.40 0.75 (0.49–1.16) 0.20
TOP1/CEN20
Continuous 0.90 (0.75–1.09) 0.28 0.74 (0.58–0.95) 0.01
Gain vs. normal 1.00 (0.72–1.39) 0.99 0.67 (0.44–1.01) 0.06
TOP1 FISH stage III 368
TOP1 signals per cell
Continuous 0.96 (0.73–1.27) 0.79 0.81 (0.58–1.13) 0.20
Gain vs. normal 0.83 (0.56–1.23) 0.35 0.69 (0.43–1.12) 0.14
TOP1/CEN20
Continuous 0.91 (0.74–1.12) 0.35 0.74 (0.56–0.97) 0.02
Gain vs. normal 1.04 (0.73–1.48) 0.82 0.70 (0.45–1.09) 0.11
TOP1 mRNA expression stage III 580
TOP1 mRNA expression
Continuous 0.85 (0.70–1.03) 0.10 0.74 (0.60–0.92) 0.007
High vs. normal 0.84 (0.61–1.15) 0.28 0.85 (0.59–1.23) 0.38
NOTE: The analyses aremade without stratifying for treatment arm. Cutoff values for TOP1 gene gain: 4 TOP1 signals per cell, TOP1/CEN20 ratio 1.5. Cutoff value
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association with OS (P ¼ 0.38). However, on a nonsignificant
level, the HRs favored high over normal TOP1mRNA expression
both in relation to RFS and OS (Table 1).
When comparing Kaplan–Meier curves, patients with TOP1
mRNAhigh classified tumors showed a trend toward an improve-
ment in RFS and OS when treated with 5FU/FA þ irinotecan
compared with 5FU/FA alone (Fig. 2). The separation of the
survival curves was statistically significant for OS (Plog-rank ¼
0.049), but not for RFS (Plog-rank ¼ 0.13). In contrast, the
Kaplan–Meier survival curves for treatment stratum in relation
to RFS (Plog-rank¼ 0.88) andOS (Plog-rank¼ 0.83) did not separate
within the subgroup of patients with tumors classified as TOP1
mRNA normal (Fig. 2). In the TOP1 mRNA high subgroup, the
relative increase in the survival probabilities at 5 years was 22%
(RFS) and 15% (OS) for patients receiving 5FU/FA þ irinotecan
compared with patients receiving 5FU/FA.
Inmultivariablemodels, the benefit of additional irinotecan on
OS in the TOP1 high subgroup was retained when adjusting for
tumor localization and KRAS status, the only two covariates
selected from univariate analysis in this subgroup. The adjusted
HR for treatment effect was 0.59 (95% CI, 0.32–1.08; PWald ¼
0.09) for RFS and 0.44 (95%CI, 0.21–0.90; PWald¼ 0.03) for OS.
Figure 1.
Kaplan–Meier estimates, TOP1 FISH stage III. A and B, RFS and OS for treatment group by TOP1 gene status, stage III. TOP1 gain: TOP1/CEN20  1.5; TOP1
normal: TOP1/CEN20 < 1.5. C and D, RFS and OS for treatment group by TOP1 gene status, stage III. TOP1 gain:  4 TOP1 signals per cell; TOP1 normal: < 4 TOP1
signals per cell.
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In contrast, the adjusted HRs for treatment effect in the TOP1
normal subgroupwere 1.02 (95%CI, 0.73–1.33;PWald¼0.90) for
RFS and 1.02 (95% CI, 0.72–1.44; PWald ¼ 0.92) for OS, thus
confirming the lack of benefit of additional irinotecan in this
subgroup.
When performing statistical tests for interaction between
dichotomized TOP1mRNA expression and treatment, the results
were nonsignificant both in relation to RFS (Pinteraction ¼ 0.16)
and OS (Pinteraction ¼ 0.07). None of the results from the explor-
atoryMFPImodels for treatment by TOP1mRNA expressionwere
statistically significant. However, the corresponding treatment-
effect plots illustrated increasing differential treatment effect in
relation to increasing TOP1 mRNA expression values (Fig. 3).
Although the confidence intervals included the log relative hazard
of 0 at any TOP1mRNA expression value, the trend for benefit of
5FU/FA þ irinotecan in patients only with TOP1 high-expressing
tumors was noticeable.
Discussion
Irinotecan is used in the metastatic setting of colorectal cancer,
but based on results from several prospective RCTs, irinotecan is
not recommended for adjuvant therapy of stage II/III colon cancer
(15–18). In the PETACC3 trial, only a nonsignificant trend was
observed in favor of additional irinotecan, suggesting that a small
subgroup of patients might obtain benefit from the irinotecan
doublet. Thus, in order to identify this subpopulation, we have
searched for predictive biomarkers for irinotecan both in preclin-
ical models of SN-38 resistant colorectal cancer cell lines and in
clinical study cohorts (34, 47). Based on published data and
results from our preclinical studies, we raised the hypothesis that
Top1, being the sole known target for irinotecan, represents a
putative key predictive biomarker for drug efficacy. Because no
validated anti-Top1 antibodies for IHC are available (30), we
analyzed the predictive property of TOP1 FISH and TOP1mRNA
expression status as a proxy for Top1 protein in relation to
additional irinotecan in the adjuvant setting of colon cancer.
We applied our validated TOP1 FISH probe combination to
available FFPE material from patients enrolled in the PETACC3
trial (17). The assay has undergone substantial analytical valida-
tion also using samples collected and analyzed in real time
(refs. 32, 48; EudraCT number 2012-002348-26). According to
predefined cutoff values, no significant differential treatment
effects were demonstrated in relation to the TOP1 gene copy
number or the TOP1/CEN20 ratio in univariate analyses.
Although simplifying statistical analyses, disadvantages of dichot-
omization of continuous variables have been addressed for sub-
group analyses in stratifiedmedicine research (41, 43, 49). Among
several pitfalls is the increased risk of type II errors as a result of the
reduction in the statistical power. To ensure that the negative
results were not caused by a biologically nonrelevant subgroup
dichotomization and to decrease the risk of type II errors by using
Table 2. Univariate predictive effects of TOP1 status in relation to recurrence-free survival
Recurrence-free survival
Patients, n Events, n 5-year rate 95% CI HR (95% CI) PWald Plog rank
TOP1 FISH stage II þ III 534
TOP1 signals per cell  4 142
5FU/FA 70 20 0.73 0.63–0.84
5FU/FA þ irinotecan 72 21 0.70 0.60–0.81 1.07 (0.58–1.97) 0.83 0.83
TOP1 signals per cell < 4 392
5FU/FA 188 60 0.70 0.63–0.76
5FU/FA þ irinotecan 204 65 0.69 0.63–0.76 1.02 (0.72–1.45) 0.90 0.90
TOP1/CEN20  1.5 167
5FU/FA 83 26 0.70 0.60–0.80
5FU/FA þ irinotecan 84 26 0.69 0.60–0.80 1.03 (0.59–1.77) 0.93 0.93
TOP1/CEN20 < 1.5 367
5FU/FA 175 54 0.71 0.64–0.78
5FU/FA þ irinotecan 192 60 0.69 0.63–0.76 1.04 (0.72–1.50) 0.84 0.84
TOP1 FISH stage III 368
TOP1 signals per cell  4 95
5FU/FA 47 16 0.65 0.53–0.81
5FU/FA þ irinotecan 48 17 0.63 0.51–0.79 1.08 (0.55–2.14) 0.82 0.82
TOP1 signals per cell < 4 273
5FU/FA 132 49 0.64 0.57–0.73
5FU/FA þ irinotecan 141 58 0.60 0.52–0.68 1.16 (0.79–1.69) 0.46 0.45
TOP1/CEN20  1.5 120
5FU/FA 61 23 0.65 0.57–0.74
5FU/FA þ irinotecan 59 24 0.61 0.53–0.70 1.13 (0.64–2.01) 0.67 0.67
TOP1/CEN20 < 1.5 248
5FU/FA 118 42 0.64 0.53–0.77
5FU/FA þ irinotecan 130 51 0.60 0.48–0.74 1.15 (0.76–1.72) 0.51 0.51
TOP1 mRNA expression stage III 580
TOP1 high 140
5FU/FA 73 29 0.60 0.49–0.72
5FU/FA þ irinotecan 67 18 0.73 0.63–0.84 0.64 (0.35–1.15) 0.13 0.13
TOP1 normal 440
5FU/FA 206 80 0.63 0.57–0.70
5FU/FA þ irinotecan 234 92 0.62 0.56–0.68 1.02 (0.76–1.38) 0.88 0.88
NOTE: The relative treatment effects (hazard ratios) are for 5FU/FAþ irinotecan vs. 5FU/FA. The P values from theWald test relate to the hazard ratios, whereas the
P values from the log rank test relate to the estimated Kaplan–Meier functions for the two treatment groups within each TOP1 subgroup. Cutoff value for high
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the full statistical power of the dataset, exploratory MFPI model-
ing was performed. This allowed for simultaneous testing of both
linear and nonlinear interaction models, where the TOP1 FISH
variables were retained on a continuous scale. None of the
adjustedbest-fitmodels identified a significant treatment byTOP1
interaction, which weighs against a predictive property of TOP1
FISH status in relation to irinotecan. The suggestions of a prog-
nostic effect of TOP1 FISH status, that is independent of treat-
ment, are interesting and confirmed previous findings (48), but
the clinical utility of the information is not apparent.
As stated, the reason why FISHwas considered an alternative to
IHC was the analytical limitations applying to the most com-
monly used anti-Top1 antibodies (30). However, limitations
apply to TOP1 FISH analysis as well. In silico analysis in the Broad
Institute Tumorscape database does not identify TOP1 as being
focally amplified in colorectal cancer, but increased TOP1 copy
numbers are identified frequently as a result of gains spanning
large parts of 20q that sometimes include the centromere region
(50, 51). This suggests that the TOP1 FISHprobe does not provide
exclusive TOP1 specific information, but rather provides generic
information about 20q aberrations that include the TOP1 geno-
mic sequence. Based on our previous observations such aberra-
tions may still be relevant in relation to prediction of irinotecan
response, but we were not able to confirm this in the setting of the
PETACC3 trial (48).
In FISH analysis intended for gene enumeration, a gene probe
and a same chromosome reference centromere probe is tradition-
ally used in combination to correct for chromosome specific
aneusomy. The gene-to-centromere ratio is a surrogate measure
of the gene-to-chromosome relationship, and ratios of 1.5
suggest the presence of at least one extra gene copy per disomic
chromosome set. Because the broad 20q gains may in some cases
overlap with the centromere region, CEN20 is not ideal for
normalization (52). For this reason we chose to include the
uncorrected raw TOP1 gene copy number data in the statistical
analyses. A parallel to this single gene approach may be drawn to
HER2 in situ hybridization (ISH) testing in breast cancer where
clinical utility is widely accepted for the identification of patients
eligible for trastuzumab therapy (53). However, there is still
debate about how to interpret the test results (54). A chromosome
17 centromere probe (CEN17) is used as a reference when
evaluating HER2 status by dual-probe ISH (53, 54). However,
gain of CEN17 is more often a result of focal peri-centromeric
duplication or 17q gains spanning the centromere region rather
than of true polysomy (53). A clinical implication of these
observations is the risk of reporting a false negative HER2 status
when relying only on the HER2/CEN17 ratio. This concern has
contributed to the 2013 revision of the American Society of
Clinical Oncology/College of American Pathologists recommen-
dations forHER2 ISH testing in breast cancer, where aHER2 gene
Table 3. Univariate predictive effects of TOP1 status in relation to OS
OS
Patients, n Events, n 5-Year rate 95% CI HR (95% CI) PWald Plog rank
TOP1 FISH stage II þ III 534
TOP1 signals per cell  4 142
5FU/FA 70 15 0.86 0.78–0.94
5FU/FA þ irinotecan 72 12 0.84 0.76–0.93 0.78 (0.63–1.66) 0.51 0.51
TOP1 signals per cell < 4 392
5FU/FA 188 44 0.77 0.72–0.84
5FU/FA þ irinotecan 204 49 0.77 0.71–0.83 1.06 (0.70–1.59) 0.79 0.79
TOP1/CEN20  1.5 167
5FU/FA 83 15 0.85 0.78–0.93
5FU/FA þ irinotecan 84 14 0.83 0.75–0.91 0.95 (0.46–1.96) 0.88 0.88
TOP1/CEN20 < 1.5 367
5FU/FA 175 44 0.77 0.71–0.83
5FU/FA þ irinotecan 192 47 0.77 0.71–0.83 0.99 (0.66–1.49) 0.96 0.96
TOP1 FISH stage III 368
TOP1 signals per cell  4 95
5FU/FA 47 12 0.83 0.73–0.94
5FU/FA þ irinotecan 48 9 0.83 0.73–0.94 0.72 (0.30–1.70) 0.45 0.45
TOP1 signals per cell < 4 273
5FU/FA 132 36 0.73 0.66–0.81
5FU/FA þ irinotecan 141 44 0.70 0.63–0.78 1.20 (0.77–1.86) 0.42 0.42
TOP1/CEN20  1.5 120
5FU/FA 61 15 0.80 0.70–0.91
5FU/FA þ irinotecan 59 12 0.79 0.70–0.91 0.83 (0.39–1.78) 0.63 0.63
TOP1/CEN20 < 1.5 248
5FU/FA 118 33 0.73 0.66–0.82
5FU/FA þ irinotecan 130 41 0.70 0.63–0.79 1.17 (0.74–1.84) 0.51 0.51
TOP1 mRNA expression stage III 580
TOP1 high 140
5FU/FA 73 24 0.72 0.62–0.83
5FU/FA þ irinotecan 67 12 0.83 0.75–0.93 0.51 (0.25–1.02) 0.056 0.049
TOP1 normal 440
5FU/FA 206 61 0.74 0.68–0.80
5FU/FA þ irinotecan 234 69 0.71 0.66–0.77 1.04 (0.74–1.46) 0.83 0.83
NOTE: The relative treatment effects (hazard ratios) are for 5FU/FAþ irinotecanvs. 5FU/FA. TheP values from theWald test relate to the hazard ratios,whereas theP
values from the log rank test relate to the estimated Kaplan–Meier functions for the two treatment groups within each TOP1 subgroup. Cutoff value for high TOP1
mRNA expression:  third quartile of the observed TOP1 expression values.
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copy number 6 signals per cell is now regarded as an unequiv-
ocally ISH positive result regardless of the HER2/CEN17 ratio.
(53). In addition, aHER2 gene copy number 4 signals per cell is
considered an equivocal result that requires reflex testing (53).
In the present study, we chose 4 TOP1 signals per cell as the
cutoff value for TOP1 gene gain for two reasons. Firstly, this cutoff
value identified 24%of stage III colon cancer with TOP1 gene gain
when using data from one of our previously published studies
(48). Although a direct comparison cannot be made to the
adjuvant setting, this number is close to the 31% overall response
rate of FOLFIRI in patients with chemo-na€ve advanced colorectal
cancer reported by Colucci and colleagues (13). Secondly, this
cutoff value is in line with the lowest threshold for equivocal
HER2 ISH results (53). For TOP1 mRNA expression, the cutoff
value was chosen to reflect the expected frequency of tumors with
TOP1 gene gain determined by FISH analysis. This was done to
ensure that a similar proportion of patients would have a poten-
tial favorable marker status for both methods of analysis.
The available mRNA gene expression data from the PETACC3
material provided us with the opportunity to test for statistical
Figure 3.
Treatment-effect plots. Multivariable fractional polynomial interaction (MFPI) treatment-effect plots for treatment effect by TOP1 mRNA expression status
in the TOP1mRNAexpression stage III population. The curves show the relative hazard (hazard ratio) on a logarithmic scale for 5FU/FAþ irinotecan versus 5FU/FA at
different values of TOP1 mRNA gene expression. The shaded areas represent the point-wise 95% confidence intervals. The plots were generated from MFPI
second-degree fractional polynomial functions. The RFS model was adjusted for N stage, KRAS status, and MSI status (n ¼ 521). The OS model was adjusted for N
stage,KRAS status, andBRAF status (n¼ 519). The adjusting covariateswere selected based on significant prognostic effects in fullmodels, including: N stage, tumor
localization, and status of: TOP1, BRAF, KRAS, and MSI. P values for interaction: RFS, P ¼ 0.34; OS, P ¼ 0.26. RFS: recurrence-free survival.
Figure 2.
Kaplan–Meier estimates, TOP1mRNAexpression stage III. A and B, RFS andOS for treatment group by TOP1mRNA status. TOP1 high: TOP1mRNA expression third
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dependence between TOP1 gene status, as measured by the two
FISH parameters, and TOP1 mRNA status. No apparent correla-
tions were observed between TOP1 gene expression and the TOP1
gene copy number or the TOP1/CEN20 ratio. This suggests that
TOP1mRNA expression is not predominantly dependent on 20q
gains involving the TOP1 locus.
Because TOP1 mRNA may be a more accurate measure of the
amount of target for irinotecan than the gene copy number, the
statistical analysis plan was also set up to explore a potential
predictive property ofTOP1mRNAexpression. Benefit of 5FU/FA/
irinotecan was observed only in the TOP1 mRNA high subgroup
(RFS: HRadjusted, 0.59 (95% CI, 0.32–1.08; PWald ¼ 0.09) and OS:
HRadjusted (95% CI, 0.21–0.90; PWald ¼ 0.03). The trend for a
TOP1 mRNA-dependent differential treatment effect was sup-
ported by the treatment-effect plots from theMFPI models. These
results are in linewith previous analysis in the neoadjuvant setting
of colorectal cancer, where high pretreatment tumor levels of
TOP1 mRNA were associated with improved response from
irinotecan-based therapy (33).
The foremost strength of this study was the use of data gener-
ated from unique tumormaterial that was prospectively collected
during the accrual of patients for a RCT that included relevant
treatment stratification for evaluation of predictive biomarkers for
irinotecan. The A þ B versus A randomization strategy of the
PETACC3 trial fulfilled the design criteria proposed by Simon and
colleagues (35) for prospective–retrospective clinical validation
of predictive biomarkers for B, in this case irinotecan. Further-
more, all biomarker populations were composed of patients who
were representative of the patients accrued to the PETACC3 trial as
a whole, i.e., randomization according to baseline patient and
tumor characteristics was retained and the treatment stratification
was well balanced.
Predictive biomarker studies in the adjuvant setting are
inherently limited by the fact that the patients fall into at least
three subsets: those who are cured by surgery alone, those who
relapse despite of chemotherapy, and those who benefit from
chemotherapy. Especially the first group may influence the
results of the statistical analyses as the outcome is not depen-
dent on the status of the predictive biomarker in question.
Although the biomarker populations were composed of up to
580 patients, the recorded number of RFS and OS events could
not ensure enough statistical power to control well for type II
errors. Simon and colleagues (35) did not define an exact
number of samples necessary for analysis, but access to material
from approximately two thirds of the original study population
was recommended, a number that we were not able to meet in
the present study. In addition, the lack of statistical power
limited us to the use of only few adjusting variables in the
multivariable models.
In relation to additional irinotecan in the adjuvant setting of
stage II and III colon cancer, this study failed to demonstrate a
predictive property of TOP1 gene copy number status, assessed by
FISH.We find the trends supporting a predictive property of TOP1
mRNA expression a positive finding. However, the results can
only be viewed as hypothesis generating, but in our opinion
further exploration of the differential treatment effect of irinote-
can-based therapy in relation to TOP1mRNA expression is highly
warranted. Based on TOP1mRNA expression, itmight be possible
to identify patients who benefit from irinotecan in the adjuvant
setting of colon cancer. However, before drawing definite con-
clusions on the clinical utility of TOP1 mRNA expression status,
the reported results need to be further studied in multiple inde-
pendent patient cohorts. In future perspectives, TOP1 mRNA
expression, possibly on a continuous scale, might become a key
biomarker in a broader panel of markers that will help clinicians
decide between irinotecan- and oxaliplatin-based doublets not
only in the adjuvant setting but also in the metastatic setting of
colorectal cancer.
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